Neumora Therapeutics (NMRA) Common Equity (2022 - 2026)

Neumora Therapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $70.7 million for Q1 2026.

• On a quarterly basis, Common Equity fell 69.05% year-over-year to $70.7 million in Q1 2026; TTM through Mar 2026 was $70.7 million, a 69.05% decrease from a year earlier, with the FY2025 full-year figure at $103.9 million, down 63.82% from the prior year.
• Common Equity retreated to $70.7 million in Q1 2026 per NMRA's latest filing, from $103.9 million in the prior quarter.
• Across five years, Common Equity topped out at $512.7 million in Q3 2023 and bottomed at -$513.5 million in Q2 2023.
• The 5-year median for Common Equity is $182.9 million (2025), against an average of $83.5 million.
• Across the five-year window, Common Equity jumped 221.49% in 2023 and sank 69.05% in 2026, its largest moves.
• Year by year, Common Equity stood at -$446.8 million in 2022, then surged by 204.97% to $469.1 million in 2023, then sank by 38.8% to $287.1 million in 2024, then plunged by 63.82% to $103.9 million in 2025, then sank by 31.95% to $70.7 million in 2026.
• Per Business Quant, the three latest NMRA Common Equity figures stand at $70.7 million (Q1 2026), $103.9 million (Q4 2025), and $132.2 million (Q3 2025).